HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Negative 62.4%

Neg 62.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.